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Abstract
Cancer cells have fundamentally altered cellular metabolism that
is associated with their tumorigenicity and malignancy. In addition
to the widely studied Warburg effect, several new key metabolic
alterations in cancer have been established over the last decade,
leading to the recognition that altered tumor metabolism is one of
the hallmarks of cancer. Deciphering the full scope and functional
implications of the dysregulated metabolism in cancer requires
both the advancement of a variety of omics measurements and
the advancement of computational approaches for the analysis
and contextualization of the accumulated data. Encouragingly,
while the metabolic network is highly interconnected and complex,
it is at the same time probably the best characterized cellular
network. Following, this review discusses the challenges that
genome-scale modeling of cancer metabolism has been facing. We
survey several recent studies demonstrating the first strides that
have been done, testifying to the value of this approach in portray-
ing a network-level view of the cancer metabolism and in identify-
ing novel drug targets and biomarkers. Finally, we outline a few
new steps that may further advance this field.
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Introduction
Recent cancer genome studies have led to the identification of
multiple cancer-associated genes and pathways (Cibulskis et al,
2013; Lawrence et al, 2014). It is clear now that cancer initiation
and progression are controlled by a host of mutational events in
these genes, combined together to support cancerous phenotypes.
Furthermore, next-generation sequencing technologies have enabled
the screening of numerous cancer types and subtypes, uncovering
both inter and intratumor heterogeneity (Lawrence et al, 2013).
Despite this large diversity in dysregulated cellular processes, many
key neoplastic events are converged to alter tumor cell metabolism.
Indeed, cancer cells were found to have a metabolism that is
remarkably different from the tissues from which they originated,
due to their high demand for proteins, lipids, nucleotides and
energy, all necessary for enhanced growth and proliferation (Vander
Heiden et al, 2009). This fundamental characteristic of cancer cells
has led to the development of the first chemotherapy treatment,
methotrexate, already in the early 1950s (Li et al, 1956), in an
attempt to target cancer cell proliferation. This drug is designed as
an antimetabolite that interferes with the use of folic acid by cancer
cells, thus blocking DNA synthesis and halting cell growth. This
common denominator among cancer cells together with additional
accumulating evidences reviewed below has recently led to the
recognition of altered tumor metabolism as one of the hallmarks of
cancer (Hanahan & Weinberg, 2011).
Cellular metabolism is finely tuned by integrating signals from
the intracellular and extracellular environments. The metabolic
switch promoting deregulated growth is often triggered by muta-
tions in signaling pathways that rest at the crux of anabolic and
energetic homeostasis, such as HIF-1a, PI3K/AKT, mTOR and
AMPK (Shaw & Cantley, 2006; Guertin & Sabatini, 2007; Wise et al,
2008; Semenza, 2010). The mutated pathways result in constitu-
tively active growth signals that induce cells to proliferate uncon-
trollably. In addition to the intracellular genetic modifications, the
abnormal environmental conditions also play a major role in modi-
fying cellular metabolism. Heterogeneity in oxygenation, PH levels
and nutrient availability are combined with intrinsically altered
tumor metabolism, optimizing for a continuous supply of building
blocks and redox potential that allow cancer cells to survive and
proliferate under strict selective pressure (Cairns et al, 2011).
Recent years have significantly advanced our understanding of
the genetic and molecular events underlying the metabolic func-
tional phenotype of cancer cells. This has been achieved due to the
considerable leap forward in omics measurement technologies,
enabling the genome-wide characterization of different altered
cellular processes. Accumulating data of gene sequences and gene
methylation patterns, gene, protein and microRNA expression
measurements, as well as metabolites levels, have revealed a
comprehensive and complex picture of dysregulated cellular
processes. Nonetheless, the entire metabolic network is comprised
of more than a hundred different subsystems, spanning a few thou-
sands of biochemical transformations. To comprehensively under-
stand how the different cellular components interact with each
other, as well as figuring how the metabolic network responds to
different genetic and environmental perturbations as a whole,
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computational tools come in hand. In particular, computer simula-
tions enabling the investigation of the network’s state under diverse
conditions and on a genome-wide level are helpful for studying both
normal and cancerous cellular metabolism, and for advancing our
ability to identify potential drug targets and biomarkers. Following,
this review will discuss our current knowledge of altered tumor
metabolism and the challenges in modeling these alterations,
through the integration of high-throughput molecular data with
state-of-the-art metabolic modeling approaches.
Metabolic alterations associated with cancer
To set up the stage for our discussion, we first provide a brief over-
view of the metabolic alterations reported to occur in cancer. For
more detailed reviews of the latter see, Cairns et al (2011), Vander
Heiden et al (2009) and Ward and Thompson (2012). One of the
most conspicuous features of cancer metabolism was already
discovered more than fifty years ago by Otto Warburg, showing that
most cancer cells utilize high amounts of glucose and secrete it as
lactate even in the presence of oxygen, a phenomenon that is
referred to as aerobic glycolysis or “the Warburg effect” (Warburg,
1956). This is in difference from normal cells that metabolize
glucose in the mitochondria via the tricarboxylic acid (TCA) cycle
and revert to anaerobic metabolism only under low oxygen condi-
tions. Today, this dramatic increase in glucose uptake by cancer
cells is exploited clinically to visualize tumors by (18F)-2-deoxy-D-
glucose positron emission tomography (FDG-PET) (Som et al,
1980). Following these early discoveries, the role of glycolysis in
cancer cells has been studied extensively and several glycolytic reac-
tions were found to be key regulators of cancer metabolism (Fig 1).
Beyond the Warburg effect, major alterations in cancer have
been identified in key pathways involved in the production of key
biomass components. As expected given the highly proliferative
nature of cancer cells (and evidenced by antimetabolite-based
chemotherapy treatment), the biosynthesis of building blocks for
nucleotide synthesis, as well as NADPH by the oxidative pentose
phosphate pathway (PPP, branching from glycolysis), is essential in
rapidly proliferating cells. Another pathway that branches from
glycolysis is serine biosynthesis, which is crucial for amino acids,
lipids and nucleotide synthesis. The up-regulation of this pathway
has been associated with the ability of breast cancer cells to metas-
tasize (Pollari et al, 2011). Furthermore, a functional genomics
screen found that some breast cancer cells rely on endogenous
serine production to sustain proliferation. Importantly, the gene
encoding for phosphoglycerate dehydrogenase (PHGDH), the
enzyme that catalyses the first committed step of serine biosynthe-
sis, is amplified and highly expressed in some cancers, and mela-
noma and breast cancer cells with PHGDH amplification divert large
amounts of glucose-derived carbons into serine and glycine biosyn-
thesis (Locasale et al, 2011; Possemato et al, 2011) (Fig 1).
Many cancer cells undergoing aerobic glycolysis require gluta-
mine carbons to replenish the TCA cycle and sustain accelerated
anabolism. In addition, glutamine is also an important nitrogen
source for cells (DeBerardinis et al, 2008). Glutamine can be deami-
nated by one of the two glutaminases (GLS1 or GLS2) producing
glutamate and ammonia. Under some conditions (e.g. hypoxia),
a-ketoglutarate produced from glutamate can undergo reductive
carboxylation to generate citrate, oxaloacetate and acetyl-CoA to
support anabolic processes anaerobically (Fig 1) (Mullen et al,
2012). As expected, GLS was found to be overexpressed in a number
of tumors, and its inhibition delays tumor growth (Lobo et al, 2000;
Wise et al, 2008).
The role of metabolism in cancer is not limited to the metabolic
adaptation to environmental changes or higher proliferation rates.
In fact, mutations affecting key metabolic pathways have recently
been found in hereditary forms of cancer or shown to increase
tumor predisposition, revealing that aberrant metabolism could also
be, in some cases, the cause of cancer. Thus, mutations in any of
the genes encoding succinate dehydrogenase (SDH) complex sub-
units were found to be the underlying cause of hereditary para-
ganglioma, a neuronal crest-derived cancer syndrome (Frezza et al,
2011a). Soon after this seminal discovery, fumarate hydratase (FH),
the enzyme that converts fumarate to malate, was found mutated in
hereditary leiomyomatosis and renal cell cancer (HLRCC) (Kiuru
et al, 2002; Tomlinson et al, 2002). Mutations in these TCA cycle
enzymes force cells to rely on a truncated TCA cycle and to accumu-
late high amounts of succinate or fumarate. It is thought that the
resulting stabilization of the oxygen-dependent labile subunit of the
hypoxia-inducible transcription factor HIFa, even in the presence of
oxygen, gives rise to a pseudo-hypoxic and aerobic glycolysis
phenotypes. Another key TCA cycle-related enzyme that was found
to be mutated in cancer cells is isocitrate dehydrogenase (IDH)
(Fig 1). An integrated genomic analysis found recurrent heterozy-
gous mutations in the active site of IDH1 and IDH2 isoforms in high
proportion of low-grade glioma and acute myeloid leukemia (AML)
patients (Parsons et al, 2008; Mardis et al, 2009; Yen et al, 2010). It
was shown that mutant IDH not only has reduced capacity to
convert isocitrate to a-ketoglutarate but also acquires a novel reduc-
tive activity utilizing a-ketoglutarate to produce 2 hydroxyglutarate
(2HG) (Dang et al, 2009), which is tumorigenic in glioma and AML.
Specific chemical inhibitors against mutant IDH1 and IDH2 have
been designed and are currently tested in clinical trials (Wang et al,
2013). Taking these findings together, fumarate, succinate and 2HG
have been dubbed as “oncometabolites,” giving rise to the possibil-
ity that other oncometabolites exist and await discovery.
Targeting tumor metabolism
As identifying new cancer drug targets is one of the main goals of
metabolic modeling in cancer, let us review the current state of
efforts to target cancer metabolism in the clinic in some detail. The
great number of dysregulated metabolic pathways provides the
opportunity for targeting these pathways pharmacologically. A
major challenge is however that the vast majority of metabolic path-
ways used by cancer cells are also essential for the survival of
normal ones, as reflected by the undesirable side effects of several
chemotherapy agents. Nonetheless, the presence of tumor-specific
enzyme isoforms or changes in the activity of a pathway may allow
preferential targeting of cancer cells. Indeed, the therapeutic effects
of targeting several metabolic enzymes have been investigated in
recent years. For instance, glycolytic inhibitors such as GLUT1
inhibitor and 2-deoxyglucose underwent clinical trials (Chan et al,
2011; Cheong et al, 2012; Gautier et al, 2013). Their effect though
was found to be limited, potentially due to the strong increase in
glutaminolysis displayed by some tumors, and the ability of tumors
with functional mitochondria to produce ATP by oxidative
Molecular Systems Biology 11: 817 | 2015 ª 2015 The Authors
Molecular Systems Biology Modeling metabolism on a genome-scale Keren Yizhak et al
2
Published online: June 30, 2015 
phosphorylation. Several inhibitors of amino acid metabolism have
also been studied. The main targeted amino acid is glutamine,
which can be depleted directly from the blood of cancer patients.
Phenylacetate reduces glutamine availability thus inhibiting cancer
cell proliferation and promoting differentiation (Samid et al, 1993;
Wise & Thompson, 2010). However, the removal of glutamine
directly from the plasma may also increase the rate at which the
body depletes its own muscle stores (cachexia). Another approach
is to target GLS directly (Seltzer et al, 2010). Further to glutamine,
asparagine and arginine biosynthesis can also be targeted by differ-
ent compounds. Although asparagine is not usually an essential
amino acid in humans due to the presence of asparagine synthetase
(ASSN), certain tumor types like leukemia have little ASSN activity
and require exogenous asparagine (Fig 1). This has led to the use of
asparaginase, the enzyme that converts asparagine to aspartate and
ammonia, for the treatment of childhood acute lymphoblastic leuke-
mia (ALL) (Haskell et al, 1969; Pieters et al, 2011). Likewise, while
in normal tissue arginine is not an essential amino acid, some
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Figure 1. Central metabolic pathways and their association with key metabolic enzymes.
Enzymes marked in red have been implicated with tumor initiation and progression and/or serve as potential therapeutic targets. G6P, glucose-6-phosphate; F6P, fructose-6-
phosphate; F1,6P, fructose-1,6-bisphosphate; F2,6P, fructose-2,6-bisphosphate; G3P, glyceraldehyde 3-phosphate; 1,3BPG, 1,3 biphosphoglycerate; 3PG, 3-phosphoglycerate;
2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate; 3PHP, 3-phosphohydroxypyruvate; Ac-CoA, acetyl-CoA; 6PGL, 6-phospho-glucono-1,5-lactone; 6PGC, 6-phospho-D-
gluconate; Ru5P, ribulose 5-phosphate; R5P, ribose 5-phosphate. PRPP, 5-phospho-alpha-D-ribose 1-diphosphate. S7P, sedoheptulose 7-phosphate; Xu5P, xylulose
5-phosphate; E4P, erythrose 4-phosphate; THF, tetrahydrofolate; mTHF, 5,10-methylenetetrahydrofolate; DHF, dihydrofolate; Mal-CoA, malonyl-CoA; aKG, a-ketoglutarate;
dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine monophosphate; TCA, tricarboxylic acid; GLUT1, glucose transporter 1; HK2, hexokinase 2; GPI, glucose-6-
phosphate isomerase; PFKFB2, 6-phosphofructo-2-kinase; PFK1, phosphofructokinase 1; PGAM, phosphoglycerate mutase; PKM2, pyruvate kinase M2 isoform; LDHA, lactate
dehydrogenase A; PHGDH, phosphoglycerate dehydrogenase; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; FH, fumarate hydratase; SDH, succinate
dehydrogenase; IDH, isocitrate dehydrogenase; GDH, glutamate dehydrogenase; GLS, glutaminase; GS, glutathione synthetase; ASCT2, solute carrier family 1, member 5;
ACL, ATP citrate lyase; ACC, acetyl-CoA carboxylase; FASN, fatty acid synthase; ASNS, asparagine synthetase; ASL, argininosuccinate lyase; ASS, argininosuccinate synthetase;
DHFR, dihydrofolate reductase; TYMS, thymidylate synthase.
ª 2015 The Authors Molecular Systems Biology 11: 817 | 2015
Keren Yizhak et al Modeling metabolism on a genome-scale Molecular Systems Biology
3
Published online: June 30, 2015 
hepatocellular carcinoma (HCC), mesothelioma and melanomas do
not express argininosuccinate synthetase (ASS) and therefore are
auxotrophic for arginine and sensitive to its depletion in plasma
(Fig 1). Arginine deiminase has proved beneficial in the treatment
of unresectable melanoma, and it is currently being tested in several
other tumor types (Feun & Savaraj, 2006; Delage et al, 2010).
Going beyond amino acid metabolism, several inhibitors of fatty
acid synthesis have also been developed and studied. Endogenous
fatty acids are synthesized from TCA cycle-derived citrate and
NADPH, which can be produced by the PPP and other enzymes.
Once in the cytosol, citrate is broken down into acetyl-CoA and
oxaloacetate by ATP citrate lyase (ACL). Fatty acid synthesis starts
with acetyl-CoA carboxylase (ACC) converting acetyl-CoA to malo-
nyl-CoA, and this is followed by a series of steps in which malonyl-
CoA and acetyl-CoA are converted to palmitate by fatty acid
synthase (FASN) (Fig 1). Many tumors therefore express high levels
of FASN, including breast, colorectal and endometrial cancers (Alo
et al, 1996), and FASN inhibitors either kill tumor cells directly or
sensitize them to other therapies such as 5-fluorouracil and
trastuzumab (Herceptin) (Kridel et al, 2004; Menendez et al, 2006;
Vazquez-Martin et al, 2007). The inhibition of other enzymes in the
de novo lipogenic pathway, such as ACL, choline kinase, ACC,
monoglyceride lipase (MGLL) and 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGCR), has proved effective as cancer treatment in
preclinical settings and these enzymes are in the focus of drug
development, and some of them, for example, statins, are currently
undergoing clinical trials (Brusselmans et al, 2005; Glunde et al,
2005; Hatzivassiliou et al, 2005; Nomura et al, 2010; Bjarnadottir
et al, 2013).
Mapping the cancer metabolome
One of the most prominent technology advancements for studying
dysregulated tumor metabolism has been the development of meta-
bolomics, a discipline that aims to measure the concentration and
relative abundance of small molecule metabolites (< 1.5 kDa) pres-
ent in biological systems (e.g. cells, tissues or body fluids) and is
currently allowing for the simultaneous measurement of hundreds
of metabolites (Dunn et al, 2005; Lane et al, 2009). The use of meta-
bolic profiling in cancer provides an additional layer of patho-
physiological information beyond genomic data. Initial metabolomics
approaches were based on nuclear magnetic resonance (NMR) but
they are now complemented with the use of mass spectrometry
(MS), which provides higher sensitivity and a wider range of metab-
olites detection (Griffiths et al, 2010). MS also offers the possibility
to perform targeted analyses of metabolic pathways by using
13C-labeled metabolites such as glucose and glutamine. This strategy
allows for the measurement of intracellular metabolic fluxes and, by
making use of partially labeled substrates, for the identification of
alternative metabolic pathways (Zamboni & Sauer, 2009). By apply-
ing these recent advances in the context of cancer research, meta-
bolic alterations have been observed in a wide variety of tumors,
identifying adaptations and vulnerabilities that open new possibili-
ties for the development of cancer therapies.
For instance, LC-MS has been used to study the metabolic altera-
tions associated with the M2 isoform of pyruvate kinase, showing
significant differences in glycolytic intermediates (Christofk et al,
2008). The same technology was used later on to show that these
glycolytic metabolites are fed into serine synthesis, allowing them to
proliferate in serine-depleted medium (Ye et al, 2012). Other meta-
bolomics flux experiments have employed GC–MS to trace central
carbon metabolism. Such studies include the finding that the reduc-
tive metabolism of a-ketoglutarate contributes to de novo lipogene-
sis (Metallo et al, 2012), the characterization of FH-deficient cells in
renal cancer (Frezza et al, 2011b), the study of glutamine dynamics
in pancreatic ductal adenocarcinoma (PDAC) (Son et al, 2013), as
well as the study of glutamine-associated changes in glioma cells
during impaired mitochondrial pyruvate transport (Yang et al,
2014). Metabolomic approaches have been additionally used to
detect cancer-specific biomarkers in body fluids. This includes the
discovery of long-chain fatty acids in the serum of colorectal cancer
patients (Ritchie et al, 2010); significant changes in amino acids,
bile acids and polar lipids in plasma samples of pancreatic cancer
patients (Urayama et al, 2010); increased levels of sarcosine in urine
samples of prostate cancer patients (Soliman et al, 2012); and more
(Armitage & Barbas, 2014).
Clearly, a great amount of data describing the metabolic altera-
tions in cancer cells has gathered in recent years, and there is a
growing need for its analysis and contextualization on a genome-
wide cellular level. A central key approach for addressing these
challenges is genome-scale metabolic modeling (GSMM), as
reviewed below.
Genome-scale modeling of cellular metabolism
One of the ultimate goals of Computational Systems Biology is to
build an in silico model of a living cell that will include all its
components and will have a predictive value in simulating all
cellular processes. A key difficulty is the lack of sufficient compre-
hensive knowledge on the pertaining biological processes and
associated detailed kinetics. However, despite these difficulties,
there is one domain where under simplifying assumptions, and
due to two hundred years of biochemistry research, we are able to
make first meaningful steps toward realizing this in silico vision,
and that is cellular metabolism (Kuepfer, 2010). Metabolism is by
now the most studied and well-known cellular process across
many species, including humans. Over the last decade, recent
strides in the computational study of metabolism have enabled its
computational investigation on a genome scale in an accelerating
pace (Herrgard et al, 2008; Bordbar & Palsson, 2012; Mardinoglu
& Nielsen, 2012; de Oliveira Dal’Molin & Nielsen, 2013; Bordbar
et al, 2014).
As reviewed above, recent technological advancements have
enabled the genome-wide quantification of gene, enzyme and
metabolite levels, thus providing cues to an organism’s metabolic
state. However, despite this considerable progress, the most direct
measure of activity in a metabolic network, the reaction flux rates,
can be measured today for only a few dozens of reactions in central
metabolism (Niklas et al, 2010). The analysis of GSMMs aims to
bridge this gap and facilitate the prediction of the network’s inner
and outer (uptake and secretion) flux rates, thus characterizing
the organism’s metabolic state on a large scale. Furthermore,
GSMM enables the integration of various omics data to obtain
context-specific metabolic descriptions, and the simulation of differ-
ent genetic and environmental perturbations under which the meta-
bolic state can be iteratively re-evaluated.
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Genome-scale metabolic model reconstruction is a manual,
bottom-up process, in which all the biochemical transformations
taking place within a specific target organism or cell are assembled
into a metabolic network (Thiele & Palsson, 2010). This network
is represented mathematically by a stoichiometric matrix that
comprises the stoichiometric coefficients of the metabolic reactions
included in the network, and is concomitantly accompanied by a
detailed mapping of the genes and proteins to their catalyzed reac-
tions (Orth et al, 2010). GSMMs typically form complex models
encompassing thousands of genes, proteins, reactions and metabo-
lites.
The analysis of GSMMs is performed via a constraint-based
modeling (CBM) approach that imposes a set of physico-chemical
constraints on the space of possible metabolic behaviors, including
mass balance, thermodynamic (directionality) and maximal flux
capacity constraints, while optimizing for a cellular objective func-
tion such as maximization of biomass yield or ATP production. The
latter is conventionally done via a flux balance analysis (FBA)
method. This approach has been extensively and quite successfully
applied for more than a decade now to study the metabolism of
microorganisms and has been rapidly expanding to dozens of manu-
ally curated models for both pro- and eukaryotes (Monk et al, 2014).
Despite its considerable predictive signal, it should be acknowl-
edged that the CBM approach makes a few simplifying assumptions
to achieve modeling on a genome scale. First and foremost, it
assumes that the system modeled is in a quasi-steady state; that is,
while internal metabolites may be generated and consumed, their
overall levels remain unchanged (while metabolites that are
exchanged with the environment may be taken up or secreted).
This assumption needs to be made since the kinetic parameters
governing the dynamics of the thousands of enzymes in the
network are mostly unknown. Second, to obtain a physiological
meaningful flux space, an additional objective function needs to be
assumed. By and large two different classes of objective functions
are assumed—(a) maximizing an assumed “cellular” objective or
(b) maximizing the fit between the predicted metabolic state and
context-specific molecular omics data. As for (a), maximizing
biomass production (a corollary of proliferation rate) is typically
used and is appealing in the context of modeling proliferating
cells like bacteria and cancer cells. Regarding (b), a variety of
approaches exist aiming to best fit the predicted metabolic state to
measured flux data, transcriptomics and proteomics, or a combina-
tion of the latter (Machado & Herrga˚rd, 2014). A detailed discussion
of the latter is beyond the scope of this review, but see some related
notes in brief in Box 1. Furthermore, it should be explicitly noted
that the models built encompass just the enzymatic reactions that
directly modify the metabolites and thus, at least in the context of
human metabolism (and in most bacterial models), do not explicitly
include interconnected cellular processes such a transcriptional
regulation and signaling pathways that regulate metabolism. Includ-
ing the latter information raises serious computational challenges as
assuming steady state is problematic in this context, but even more
so, they are simply yet not known at a sufficient level of details.
Additionally, while when simulating cell line experiments the
growth media is well characterized, regrettably, in simulating
in vivo systems (like the metabolism of healthy or tumor tissue) the
environment is not well characterized and one needs to make some
bold assumptions regarding its composition. Finally, in the key
application of GSMMs to predict new cancer drug targets, one
should note that many relevant factors are actually out of the scope
of such an endeavor, including the “druggability” of a predicted
target, its cellular localization, its three-dimensional structure and
its potential binding with known classes of inhibitors (Hopkins &
Groom, 2002; Bunnage, 2011).
Genome-scale modeling of human metabolism
Genome-scale metabolic modelings of human metabolism (Table 1)
have been reconstructed to represent the collection of all the meta-
bolic reactions known to occur in human cells (Duarte et al, 2007;
Ma et al, 2007; Mardinoglu et al, 2013a, 2014; Thiele et al, 2013).
These models have been utilized for modeling both normal and
diseased human metabolism, as comprehensively reviewed by
Bordbar and Palsson (2012), Mardinoglu and Nielsen (2012). In
contrast to the modeling of microorganisms, two crucial points
should be taken into consideration when utilizing these human
reconstructions: (i) First, the models are not specific to any tissue or
cell type. As they encompass the set of all possibly occurring human
metabolic reactions, their solution space contains multiple feasible
metabolic behaviors that should be further constrained to achieve a
level of cell or tissue specificity; (ii) second, the objective function
(s) of different human tissues and cells is more difficult to determine
(or perhaps even does not exist), especially for those cells that are
non-proliferating (and hence maximal biomass yield cannot be
assumed). Considering these challenges, the question is then how
Box 1: Building tissue/cell-specific human GSMMs
In general, methods for integrating omics datasets can be classified
into those that use a discrete representation of the input data and
those that utilize a more quantitative approach:
The first type categorizes the model’s reactions into two groups: those
associated with highly and those associated with lowly expressed
genes. They then apply different types of objective functions aiming
to maximize the similarity between this discrete representation and
the model’s reaction activity state (Becker & Palsson, 2008; Jerby et al,
2010; Shlomi et al, 2011; Agren et al, 2012; Wang et al, 2012b) (Fig 2).
This discrete representation of the expression state might not be
sensitive enough for modeling the differences between cells that
exhibit only subtle variations in their expression level. Despite some
limitations, these approaches have been successfully used as a basis
for generating context-specific models of tissues and cells through
which both normal and diseased human metabolism have been stud-
ied (Bordbar & Palsson, 2012; Mardinoglu et al, 2013b; Oberhardt
et al, 2013).
The second, non-discretized approach utilizes the absolute gene
expression levels to derive a flux description of a specific metabolic
state (Lee et al, 2012), or for constraining reactions’ maximal flux
capacity for the purpose of building a specific model (Colijn et al,
2009; Fig 2). While these approaches maintain the basic structure of
the network and are more sensitive to subtle differences in expression
levels, their drawback is in their underlying implicit assumption that
there is a strong monotonic positive association between gene expres-
sion levels and flux rates, an assumption that is known to hold only
partially (Bordel et al, 2010). Applying this approach while utilizing
proteomic data can potentially improve model accuracy. These
approaches have so far mostly been applied for studying microorgan-
isms. Their application to the study of higher organisms in the context
of mammalian physiology and cancer metabolism has only recently
been established (Yizhak et al, 2014a).
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can we utilize these reconstructions to study normal and diseased
human metabolism?
Simulating genetic and environmental perturbations
Once a specific metabolic model has been reconstructed, it can be
utilized to predict cellular responses to genetic and environmental
perturbations. The set of genetic perturbations that can be simulated
via a GSMM includes both complete (knockout) and partial
(knockdown) gene deletions (Orth et al, 2010), as well as gene over
expression (Wagner et al, 2013). Environmental perturbations may
be simulated by changing media composition, modifying the quanti-
ties of available metabolites as well as enforcing their uptake into
the cell (Mo et al, 2009) (Fig 2). Another type of perturbation is at
the intracellular metabolite level, where a metabolite deficiency
is simulated by its removal from the network (Kim et al, 2007).
The various perturbations described above can be simulated in all
Table 1. Human model reconstructions and their usage in cancer metabolism. The table describes the size of the different reconstructions and
their specific application in the study of different cancer cells and tissues.
Human model
reconstruction
Size
Cancer type Application ReferencesGenes Reactions Metabolites
Recon 1
(Duarte et al, 2007)
1,905 3,742 2,766 Generic Studying the association between cell
proliferation and the Warburg effect
Shlomi et al (2011)
Generic Pathway contribution to NADPH
production in cancer
Fan et al (2014)
Generic Identification of cancer-selective
drug targets
Folger et al (2011)
Generic Predicting combinations of anti-cancer
drugs with minimal side effects
Facchetti et al (2012)
26 tumor tissues Identifying cancer-specific metabolic
pathways
Wang et al (2012b)
Liver cancer
cell line
Identifying P53-associated metabolic
changes
Goldstein et al (2013)
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possible combinations, and each time the resulting metabolic state
of the cell can be re-evaluated. However, the question is what can
we assume about the cellular objective function following such
perturbations?
Similar to the simulation of wild-type states, the maximization
of biomass yield and ATP production have been extensively used
for evaluating the post-perturbation metabolic state (Orth et al,
2010), both in microorganism and in cancer cells (Fig 2).
However, alternative objective functions have also been applied,
suggesting that in the perturbed state the cell tries to minimize the
deviation from its previous wild-type state (Segre et al, 2002;
Shlomi et al, 2005). Interestingly, it was shown that while the first
approach represents the outcome of long-term evolutionary pres-
sure, the second one is more suitable for cases that do not possess
a mechanism for immediate regulation of fluxes toward the opti-
mal growth configuration (Segre et al, 2002). Despite the fact that
these approaches do not consider any condition-specific high-
throughput data, they have been successfully used for various drug
discovery applications (Kim et al, 2010; Shen et al, 2010; Folger
et al, 2011), as well as metabolic engineering tasks (Bro et al,
2006; Anesiadis et al, 2008), reductive evolution simulations (Pa´l
et al, 2006; Yizhak et al, 2011), gene essentiality predictions
(Duarte et al, 2004; Oh et al, 2007; Orth et al, 2011) and more
(Oberhardt et al, 2009). Nonetheless, the era of large-scale omics
data provides an opportunity for determining the perturbed state
without the need to assume a pre-defined objective function
(Fig 2). Yizhak et al (2013) have developed a new algorithm that
utilizes source and target gene expression data to predict perturba-
tions that are most likely to transform the metabolic state from
one state to the other. The algorithm was applied to study yeast
and mammalian aging and led to the identification of novel
lifespan-extending genes.
Genome-scale modeling studies of cancer metabolism
In recent years, many systems biology studies have been collecting
molecular omics and phenotypic data for studying cancer. The avail-
ability of such high-throughput omics data provides the opportunity
of integrating this data within a generic human GSMM to infer the
metabolic activity state characterized by these measurements, in a
cell-specific and condition-dependent manner (Jerby & Ruppin, 2012;
Lewis & Abdel-Haleem, 2013) and, importantly, without the need to
define a cellular objective function see ((Machado & Herrga˚rd,
2014), Box 1). Omics integration has been mainly used toward two
main goals: (i) characterizing the metabolic state of different cancer
cells and studying fundamental cancer-related phenomena and
(ii) identifying cancer metabolic drug targets and biomarkers in a
context- and type-specific manner (Fig 3).
Studying cancer-related metabolic phenotypes
To describe the metabolic alterations in cancer, several GSMM stud-
ies have looked into alterations in central metabolism that are
common among tumors, such as aerobic glycolysis (the Warburg
effect) and enhanced biomass production and proliferation
(Resendis-Antonio et al, 2010; Folger et al, 2011; Shlomi et al, 2011;
Vazquez & Oltvai, 2011). By utilizing a metabolic model of central
metabolism Vazquez et al (2010) and Vazquez and Oltvai (2011)
have shown that at low glucose uptake rates mitochondrial respi-
ration is indeed the most efficient pathway for ATP generation.
However, above a threshold of metabolic rate, activation of
aerobic glycolysis is favoured because it provides higher ATP
production per volume density than mitochondrial oxidative
phosphorylation. Studying this phenomenon on a genome scale
Shlomi et al (2011) have shown that the Warburg effect may be a
direct consequence of the metabolic adaptation of cancer cells to
increased biomass production rate. Their model captured a three-
phase metabolic behavior that is observed experimentally during
oncogenic progression. Recently, Yizhak et al have studied the role
of the Warburg effect in supporting cancer cell migration, trying to
extend our understanding of this phenomenon beyond its associa-
tion with cellular proliferation. Computing the predicted ratio of
glycolytic ATP flux rate versus the oxidative one across different
cancer cell lines, a strong positive significant association with cell
migration was identified, thereby suggesting an additional role of
the Warburg effect in supporting later stages of tumor progression.
Apart from the Warburg effect, the generic human model has been
recently used to study the relative contribution of different meta-
bolic pathways to NADPH production, showing that 40% of
NADPH production is predicted to come from one-carbon metabo-
lism mediated by tetrahydrofolate (THF), an observation that was
thoroughly experimentally verified in this study (Fan et al, 2014;
Fig 3).
Other GSMM studies have integrated cancer omics data to char-
acterize a cancer-specific metabolic behavior. The first step in this
direction was taken by Folger et al, who have generated a generic
genome-scale model of cancer metabolism based on a core set of
cancer-related enzymes. This model captured the main metabolic
functions shared by many cancer types and has shown to success-
fully identify genes that are essential for tumor growth (Folger et al,
2011). Moving toward tumor-specific GSMMs (Agren et al, 2012;
Wang et al, 2012b), Agren et al have constructed metabolic models
for 16 cancer types and their parent tissues, predicting metabolites
that are significantly more involved in the metabolism of cancer
Figure 2. Genome-scale metabolic modeling as a platform for predicting flux distributions and simulating cellular perturbations.
Genome-scale metabolic modelings (GSMMs) provide an opportunity to characterize a cellular metabolic state by predicting the distribution of the network’s reaction flux
rates on a genome-scale level. For the analysis of microorganisms, this has been mostly achieved by assuming a pre-defined cellular objective function such as maximization
of biomass yield or ATP production (left section, upper panel). Such an objective function cannot always be assumed when analyzing human metabolism, and therefore,
omics data are utilized to derive a reduced specific model or characterize a metabolic flux state that best fits the context-specific omics data. The data can be used
either in a discrete manner (left section, middle panel), trying to activate the flux thorough reactions associated with highly expressed genes (green) while removing those
associated with lowly expressed genes (red), or constraining the model more quantitatively by considering the absolute expression levels (as depicted by the different
colors, left section, lower panel). The network can be further studied by simulating genetic and environmental perturbations (right section). Similarly, the flux
through the perturbed network can be derived based on a pre-defined objective function (right section, upper panel) or by utilizing the omics data to define the differential
expression signature that can then be used to constrain the model in various ways (right section, lower panel).
◀
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cells, such as polyamines, isoprenoid and eicosanoid metabolites, in
correspondence with recent reports in the literature (Fig 3). Later
on, the same group has used a more comprehensive human model
reconstruction (Mardinoglu et al, 2013a) to build tumor-specific
models for breast, bladder, liver, lung and renal cancer tissues based
on their proteomic signatures. A topological network analysis of
these models has shown that clear cell renal cancer demonstrates a
metabolic shift that associates differential down-regulation of
one-carbon metabolism enzymes with poor clinical outcome.
Interestingly, specific defects in nucleotides, one-carbon and
glycerophospholipid metabolism that are unique to this type of
cancer could be explained by loss of heterozygosity in multiple
metabolic genes adjacent to the von Hippel-Lindau (VHL) tumor
suppressor, which is frequently deleted in this type of cancer (Gatto
et al, 2014). An alternative custom-built set of 26 tumor models was
used by Wang et al (2012b) to identify tumor-enriched pathways
according to model-based flux distributions, going beyond those
predicted using differential gene expression alone. Lastly, focusing
on specific cancerous mutations Goldstein et al (2013) have used
the generic human metabolic network to characterize the metabolic
state of liver-derived cancerous cells with a varying p53 status, with
their results suggesting that P53 diverts glucose away from growth-
promoting pathways to gluconeogenesis, thereby inhibiting onco-
genesis (Fig 3).
Moving toward the analysis of larger cohorts of cancer cells,
Dolfi et al (2013) have integrated cell volume measurements,
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estimated DNA content and exchange fluxes of the NCI-60 cell
lines, and showed that nutrient exchange rates are correlated with
cell proliferation only when the variability in cell size is taken
under consideration (Fig 3). At the intersection of cancer cell lines
and clinical samples, Feizi et al have identified metabolic subnet-
works based on the generic human model and gene expression
levels collected from both the NCI-60 cell lines collection and
colon cancers. Interestingly, many of the major subnetworks that
were found to be positively and significantly associated with
cancer cell line proliferation were found to be negatively associ-
ated with patients’ survival (Feizi & Bordel, 2013). On the clinical
side, Jerby et al have used gene expression and proteomics
derived from breast cancer patients to perform a GSMM analysis
of their tumors, showing that advanced breast cancers have an
increased flux in glycolysis, lactate production and ROS detoxifica-
tion. The model’s predictions of proliferation rates, ROS produc-
tion and biomarkers were experimentally validated. The latter
investigation also revealed a fundamental inherent stoichiometric
trade-off between serine and glutamine metabolism, which under-
lies key metabolic differences between the ER+ and ER subtypes
(Jerby et al, 2012).
Identifying perturbations targeting cancer metabolism
The analysis of different cancerous cells and states provides the
opportunity for predicting new cytotoxic drug targets through the
genome-scale predicted effects of various cellular perturbations. A
deeper analysis involving richer datasets can extend upon that and
address more complex challenges such as drug selectivity and drug
resistance, as well as the targeting of other metabolically related
cancerous alterations.
Several studies aiming to accomplish these goals have been
published in recent years. The generic cancer model built by Folger
et al (2011) has been used to predict 52 cytostatic drug targets, of
which 40% were targeted by either approved or experimental anti-
cancer drugs at the time of its publication. The same approach has
later been used by Frezza et al (2011b) to build a cancer cell-specific
model of newly characterized genetically modified kidney mouse
cells in which Fh1 has been deleted, thus studying the germline
mutation of fumarate hydratase (FH) responsible for HLRCC. The
HLRCC model has been used for identifying selective drug targets
through a synthetic lethality (SL) approach and led to the identifica-
tion of enzymes along the heme biosynthesis pathway as potential
SL-pair targets of FH. Indeed, experimental validation of such a
target, HMOX, was shown to selectively kill FH-deficient cells while
sparing the normal ones (Fig 3).
Exploring the effects of currently available drugs Facchetti et al
(2012) have developed a novel GSMM-based method to investigate
potential synergies between metabolic drugs, thus predicting opti-
mal combinations of anti-cancer drugs with minimal side effects on
normal human cell. Li et al (2010) have similarly utilized informa-
tion on existing drugs and investigated flux predictions for the
NCI-60 set of cell lines. This investigation identified drug-reaction
interactions that were then used to predict new targets for approved
anti-cancer drugs. Further along these lines Asgari et al (2013) have
performed a topological analysis for 15 normal and cancer-specific
metabolic networks, showing that approved anticancer metabolic
drugs are not associated with highly connected enzymes, as may
have been expected.
Recently, Agren et al have searched for antimetabolites aiming
to target multiple enzymes simultaneously. Applying this approach
for personalized models of six hepatocellular carcinoma patients
has predicted 147 such potential antimetabolites. Out of which, the
analogs of l-carnitine were studied experimentally by examining
the effect of perhexiline, an inhibitor of carnitine palmitoyltransfer-
ase 1 (CPT1) on the proliferation of a HepG2 cell line, showing
reduced viability of these cells (Agren et al, 2014) (Fig 3). In a
recent study, cell-specific models of a few hundreds of normally
proliferating and cancerous cell lines were built by the quantitative
integration of their gene expression levels (Yizhak et al, 2014a).
These cell-specific models were then shown to successfully predict
metabolic phenotypes on an individual level, including cellular
proliferation rate, biomarkers and drug response. These models
were also used to identify selective drug targets, which has led to
the experimental validation of a top predicted selective target,
MLYCD, in both a leukemia and kidney cancer cell lines versus
their normal counterpart. A mechanistic investigation of the cyto-
toxic effect induced by MLYCD deficiency has demonstrated the
potential role of oxidative stress in this process (Yizhak et al,
2014a; Fig 3). As briefly described above, these cancer models
were then used to predict the ratio between glycolytic and oxida-
tive ATP production rate, showing its positive association with cell
migration. Following, a dozen of novel gene perturbations that
were predicted to reduce this ratio were found experimentally to
significantly attenuate cell migration, while having almost no effect
on cellular proliferation, as predicted. Importantly, such targets
may reduce cytotoxic-related clonal selection of more aggressive
cancer cells and the likelihood of emerging resistance (Yizhak
et al, 2014b; Fig 3).
Taken together, these studies clearly demonstrate the consider-
able potential value of GSMMs in deciphering the metabolic under-
pinnings of different tumorigenic phenotypes. Those include the
fundamental characteristic of increased cell proliferation, as well as
less metabolically direct cancerous phenotypes such as increased
cellular migration and invasion. In addition, the various drug targets
and biomarkers already revealed by GSMM-based studies and
further validated experimentally testify for their ability to capture
network-wide level effects that could not have been identified by
data analysis alone.
Future challenges in the modeling cancer metabolism—
what lies ahead?
While there has been a remarkable progress in the last 4 years in
the genome-scale modeling of cancer metabolism, additional chal-
lenges lie ahead in terms of both methodological and translational
advancements. These include the utilization of richer datasets
from both cell lines and clinical samples, the consideration of
different cellular regulatory mechanisms, the modeling of cancer
cell environment including its interactions with surrounding cells,
and studying and assessing the potential of emergent drug resis-
tance to metabolic cancer drugs. Further in the future, as more
detailed kinetic information on specific central metabolism in
humans is gathered, one may begin to address the challenge of
building integrated kinetic and stoichiometric models of cancer
metabolism.
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Integrating additional omics data sources
As reviewed above, the GSMM framework is a platform for omics
data integration that can be of significant value. Nonetheless, trans-
criptomics and proteomics have been the main data source for deci-
phering metabolic phenotypes, while other data sources have been
rarely used.
New technology for next-generation sequencing (NGS) has
enabled a systematic cataloging of cancer genomes through
national and international genomics projects (Simon &
Roychowdhury, 2013). The Cancer Genome Atlas and the Interna-
tional Cancer Genomics Consortium are examples for such
comprehensive resources where mutational signatures and poten-
tially new therapeutic targets across cancer types have been iden-
tified (Alexandrov et al, 2013; Yang et al, 2013a). By focusing on
the subset of mutated metabolic enzymes and evaluating their
effect on protein function, one can potentially use these datasets
to model multiple cancer subtypes and identify their unique meta-
bolic vulnerabilities (Fig 4). A first step in this direction has been
recently taken by Nam et al (2014). In this study, the authors
integrated genetic mutation data from more than 1,700 cancer
genomes along with their gene expression levels. Predicted flux
changes between normal and cancer cells were then evaluated
by simulating loss-of-function mutations in metabolic enzymes,
leading to the prediction of 15 predicted oncometabolites,
reassuringly including the well-known oncometabolites succinate
and fumarate.
Apart from genomics, metabolomics is an additional accumulat-
ing data resource for studying cancer biology. Metabolomic profiles
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Figure 4. Current and future applications of GSMMs.
In the context of cancer metabolism, Genome-scale metabolic modelings (GSMMs) have been applied for studying fundamental cancer phenotypes that are either
generic or tumor/cell-specific and for identifying drug targets that inhibit cancer-related phenotypes such as proliferation and migration in a specific and selective manner.
GSMMs can also be used for addressing emerging challenges in cancer therapy such as drug resistance. Furthermore, the analysis of GSMMs can be extended by
integrating additional omics data such as genomics and metabolomics and by utilizing the information on post-transcriptional and post-translational integration as well as
incorporating allosteric regulation effects. Another challenge is the modeling of the interaction between cancer cells and supporting cells in their environment.
Environmental effects can also be modeled by integrating structural analysis and predicting the effects of environmental conditions (which cannot be modeled
directly) on enzyme activities.
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of cancer cells have been widely used for the past several years to
distinguish between different cell lines and tumor types both in vitro
and in vivo (Florian et al, 1995; Tate et al, 1998). Furthermore,
cancer-associated mutations in certain metabolic genes were found
to induce an abnormal accumulation of oncometabolites (Yang
et al, 2013b). For instance, as already described above, mutations in
IDH1 and IDH2 result in the generation of 2-hydroxyglutarate
(2HG), which alters gene transcription through DNA modifications
and histone methylation (McCarthy, 2013). The ability to both inte-
grate and predict metabolite concentrations on a genome-scale level
is therefore of major importance in studying cancer metabolism
(Fig 3). While information on extracellular metabolites has been
used to constrain a given GSMM (Agren et al, 2012; Schmidt et al,
2013), the prediction and/or integration of intracellular metabolite
levels requires the usage of thermodynamic information and the
knowledge of the kinetic parameters (Yizhak et al, 2010; Cotten &
Reed, 2013), which are largely unknown. The utilization of meta-
bolomic data for analyzing GSMMs therefore calls for new, more
sophisticated methodologies designed to address these emerging
challenges.
Accounting for different cellular regulatory mechanisms
The great majority of GSMM-based cancer studies rely solely on the
metabolic–stoichiometric aspects of the human network and its inte-
gration with different omics datasets. The next step extending upon
that is the integration of different regulatory mechanisms, including
transcriptional and post-transcriptional regulation (Fig 4). Methods
for developing integrated metabolic–regulatory GSMMs have
already been developed and studied in microorganism (Covert et al,
2004; Herrgard et al, 2006; Shlomi et al, 2007). The computational
machinery for achieving this goal can therefore be readily used for
higher organisms as well. Nonetheless, information on the architec-
ture of the human regulatory network and its complexity has only
recently been starting to accumulate through projects such as the
ENCODE (Consortium, 2012). Utilizing these newly incoming rich
data resources to reconstruct a human metabolic–regulatory
network model is of tremendous potential in accelerating the model-
ing of human metabolism in general, and cancer metabolism in
particular.
Additional genomic regulatory information that can be used to
account for different cancerous cellular states is microRNA (miRNA)
levels and epigenetic modifications. miRNA alterations were already
found to be involved in the initiation and progression of human
cancer, as reflected by the widespread differential expression of
miRNA genes in malignant compared to normal cells (Calin & Croce,
2006). Recently, Wu & Chan (2014) have integrated miRNA-target
prediction, metabolic modeling and context-specific gene expression
data to predict therapeutic miRNAs that could reduce the growth of
cancer. This approach has been applied to human hepatocellular
carcinoma (HCC) wherein overexpression of each miRNA was simu-
lated to predict their ability to reduce cancer cell growth. Remark-
ably, the overall accuracy in predicting the miRNAs that could
suppress metastasis and progression of liver cancer was > 80%. An
additional type of regulation that has not been widely studied yet is
that of allosteric regulation. The incorporation of allosteric (in)acti-
vation information concerning metabolic enzymes is currently miss-
ing from the basic GSMM analysis and can certainly boost its
predictive power (Fig 3).
Modeling cancer cells environment and interactions
While many studies have focused on growing cancer cells in vitro
and out of their tumorigenic context, it is now widely accepted that
the tumor microenvironment plays an important role in defining
and reprogramming cancer cell metabolism (Morandi & Chiarugi,
2014). The computational study of cell and tissue interactions via
GSMMs has already been demonstrated in both microorganisms
and human tissues (Bordbar et al, 2011; Freilich et al, 2011;
Zomorrodi & Maranas, 2012), but has not been explored in the
context of cancer cells and supporting cells in their environment.
Modeling the dynamic exchange of material between these different
cells can bring us closer to a more accurate modeling of tumors
in vivo and reveal metabolically related phenotypes that could not
have been discovered by the modeling of each cancer cell alone
(Fig 4).
Apart from the interaction with other cells in their microenviron-
ment, cancer cells are also exposed to varying oxygen and pH
levels. These factors play a key role in tumor development and are
known to affect tumor cell metabolism (Helmlinger et al, 1997).
While oxygen and nutrient availability in general can be simulated
directly via GSMMs, the simulation of environmental factors such
as pH is less straight forward. One possible approach for addressing
this challenge is by applying structural analysis to predict the effect
induced by pH levels over the activity of metabolic enzymes
(Fig 4). Interestingly, a conceptually somewhat analogous analysis
has been applied to study Escherichia coli response to diverse
temperatures, revealing protein activities that limit network func-
tion at higher temperatures and providing mechanistic interpreta-
tions of mutations found in strains adapted to heat (Chang et al,
2013).
Studying the emergence of resistance to metabolic drug targets
Resistance to chemotherapy and molecularly targeted therapies is a
major problem facing current cancer research, and the mechanisms
for its acquirement are diverse (Gottesman, 2002). GSMMs can be
utilized in this context to identify promiscuous functions of existing
metabolic enzymes, thus revealing alternative pathways capable of
bypassing the targeted oncogenic reaction(s). Furthermore, this
approach can be used to identify gain-of-function enzyme mutations
and increase our understanding of enzymes’ catalytic side activities
(Fig 4). Promiscuous functions of metabolic enzymes have already
been studied by GSMM of Escherichia coli, both revealing funda-
mental features of these enzymes (Nam et al, 2012) and identifying
novel metabolic pathways that produce precursors for cell growth
under diverse environmental conditions (Notebaart et al, 2014). In
addition to that, the GSMM framework also enables the simulation
of multiple perturbations simultaneously and can thus facilitate the
investigation of drug combinations therapy and SL-based treat-
ments. These investigations provide an opportunity for achieving
greater selectivity and specificity, offering tremendous potential for
improved prognoses.
In closing, one should note that in addition to GSMMs, other
more early approaches exist for the modeling of biological
processes, including large-scale topological and Boolean networks,
and the more classic, small-scale analyses through ordinary differen-
tial equations (ODE) (Resendis-Antonio et al, 2014). The detailed
review of these approaches is beyond the scope of the current paper.
Here we just note in brief that topological networks have been used
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for studying how genes coordinate their expression in various
biological states, and were applied to identify drug targets in differ-
ent contexts, including glioblastoma, breast and cervical cancers
(Horvath et al, 2006; Higareda-Almaraz et al, 2011; Wu & Stein,
2012). On the other hand, Boolean network analyses involve the
modeling of the dynamics of transcription regulatory and signaling
networks (Wang et al, 2012a), and were used for identifying genes
driving the transitions between different tumor progression stages,
and determining driver mutations that promote cancerous pheno-
typic transitions as a function of the cell’s microenvironment (Fumia˜
& Martins, 2013; Srihari et al, 2014). ODE models were mainly used
in this context for studying the dynamics of tumor growth (Laird,
1964) and understanding tumors’ response to therapy (Lankelma
et al, 2013). Though challenging, the combination of these different
approaches can bring us closer toward the holy grail of whole-cell
modeling, which we proceed to discuss in our concluding remarks.
Conclusions
As evident, genome-scale metabolic modeling provides valuable
insights into cancer metabolism and holds promise for many more
interesting and clinically relevant applications to come. Importantly,
GSMM is a stepping stone for whole-cell modeling, and this vision,
which was already firstly realized by Karr et al (2012) in bacteria,
should inspire us to aim at modeling the entire cellular dynamics of
different cancer cells. While clearly cancer cells represent a much
more complex system, we should bear in mind that the enormous
amount of data accumulated by the scientific community about
cancer, and the pace in which it grows, is orders of magnitude larger
than any other cellular system. The initial strides discussed here for
GSMMs demonstrate that, perhaps, “yes, we can.”
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